Abstract
PROCEPT BioRobotics will report fiscal results on August 04, 2026 Post Market; this preview outlines consensus expectations for revenue, margins, net results, and adjusted EPS, reviews last quarter’s print and segment mix, and synthesizes Street views into a single actionable outlook for the upcoming quarter.
Market Forecast
Consensus for the current quarter points to total revenue of 92.89 million US dollars with year-over-year growth of 21.59%, estimated EBIT at -27.46 million US dollars with year-over-year improvement of 6.18%, and estimated adjusted EPS at -0.46 with an expected year-over-year improvement of 10.16%. Forecast commentary anticipates continued strength in the recurring disposables stream and expanding utilization, while losses narrow on operating leverage; the consumables franchise is poised to be the principal growth engine with revenue scale accelerating year over year.
The most promising segment is the handpieces and other consumables line, projected to remain the largest revenue contributor; last quarter this category generated 49.39 million US dollars, and continued procedure growth suggests robust double-digit year-over-year expansion ahead.
Last Quarter Review
In the prior quarter, PROCEPT BioRobotics delivered revenue of 83.13 million US dollars, a gross profit margin of 64.89%, GAAP net loss attributable to the parent company of 31.64 million US dollars, a net profit margin of -38.06%, and adjusted EPS of -0.56 with year-over-year growth of -24.44%.
Quarter-on-quarter, net loss narrowed by 6.01%, reflecting sequential cost discipline and scale benefits as the installed base expands. By mix, main business revenue was led by handpieces and other consumables at 49.39 million US dollars, followed by system sales and rentals at 27.24 million US dollars and services at 6.50 million US dollars, consistent with a model that monetizes procedures on a growing base.
Current Quarter Outlook
Main commercial engine: recurring disposables and procedure-linked revenue
The company’s recurring revenue model centers on handpieces and other consumables tied to each procedure, which represented 59.41% of last quarter’s sales at 49.39 million US dollars. With guidance and Street models calling for 92.89 million US dollars this quarter, the setup implies continued double-digit procedure growth as utilization remains healthy across existing accounts and new centers ramp usage. Gross margin resilience around the mid-60% area last quarter supports the view that product mix and cost curves can offset pricing pressure, while scale in manufacturing and logistics underpins incremental leverage.
Sustained procedure growth is likely to remain the core driver for top-line expansion, with seasonality modest in the reported quarter given typical hospital capital and operating budget cycles. Salesforce productivity and training throughput will influence conversion and utilization, while supply continuity and back-order dynamics could shape intra-quarter variability.
Highest near-term growth vector: installed base expansion via systems and rentals
System sales and rentals contributed 27.24 million US dollars last quarter, or 32.77% of total revenue, and act as a forward indicator for future disposables demand. Capital placements to new hospitals and ambulatory sites tend to seed multi-year consumables revenue; thus, even if capital cycles soften, rental structures can preserve adoption momentum and reduce upfront barriers. The forecast EBIT trajectory suggests operating losses narrowing as go-to-market productivity improves and per-site utilization climbs.
Key watch items this quarter include the pace of new account openings, order conversion from pipelines built in the first half of the year, and the balance between outright purchases and rental agreements. A stable or rising placement trend would validate the implied acceleration in procedure-linked consumables sales into the back half.
Stock-price swing factors: margin cadence, operating leverage, and capital placement mix
Investors are set to focus on three elements: revenue execution against the 92.89 million US dollars bar, gross margin relative to the prior 64.89% level, and the rate of operating loss improvement versus the -27.46 million US dollars EBIT estimate. Upside could come from stronger-than-modeled disposables pull-through and a favorable mix of higher-margin consumables, while downside risks would be tied to slower-than-expected capital placements, extended sales cycles, or a shift toward lower-margin configurations. Net margin sensitivity remains high to opex phasing in commercial expansion and R&D, so commentary on hiring pace and spending discipline will influence forward EPS paths.
Management’s color on backlog, procedure growth by cohort, and any updates on cost-down initiatives across manufacturing and logistics will guide how quickly adjusted EPS can track toward breakeven from the -0.46 expectation. Any indication of improved throughput in training and proctoring could translate into higher utilization and stronger recurring revenue in subsequent quarters.
Analyst Opinions
Across recent analyst commentary, the dominant stance is bullish, citing resilient procedure growth, continued gross margin support in the mid-60% range, and a clear path to narrowing losses as utilization scales; bearish notes remain in the minority and generally focus on capital spending sensitivity and competitive dynamics. Several well-followed brokers expect revenue around 92.89 million US dollars with year-over-year growth near 21.59% and emphasize the durability of the consumables franchise as the key support for estimates; the majority view highlights upside potential if placements outpace plans and pull-through remains strong. In short, the prevailing perspective anticipates in-line to modestly above-consensus revenue, stable to improving margins, and a constructive trajectory for adjusted EPS against the -0.46 benchmark.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments